publication date: Aug. 30, 2014

html NCI CTEP.html

NCI CTEP-Approved Trials for the Month of August

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

9571: A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. University of Texas MD Anderson Cancer Center; LAO Lieu, Christopher Hanyoung. (303) 724-6390

Phase I/II

9577: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma. NCI Lymphoid Malignancies Branch; Dunleavy, Kieron Michael. (301) 435-1007

Phase II

9568: A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers. University Health Network-Princess Margaret Hospital; Oza, Amit M. (416) 946-2818

NRG-LU001: Randomized Phase II Trial of Concurrent Chemoradiotherapy Metformin HCL in Locally Advanced NSCLC. NRG Oncology; Tsakiridis, Theodoros. (905) 387-9495

S1314: A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. SWOG; Flaig, Thomas W. (303) 724-3888

S1406: Randomized Phase II Study of Irinotecan and Cetuximab with or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer. SWOG; Kopetz, Edmund Scott. (713) 792-2828

Phase III

ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy … Continue reading CCL August – NCI CTEP-Approved Trials

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.